Fielmann

Fielmann is the German optical-retail giant that quietly transformed 2022-2025 from a domestic-only mid-cap into a 5-country, 1.000+ store retailer with US footprint via the SVS Vision acquisition. The company operates 880 stores in DACH + Italy + Spain + Poland (added through Optical Discount + GrandVision divestiture pickups) plus 240 stores in US (SVS Vision Q3/2024 close). FY25 revenue EUR 2.4 B (+8.4% YoY organic + acquisition), EBIT margin 14.2%. Founder Günther Fielmann passed in 2023; his son Marc Fielmann took CEO role in 2018 and runs the company alongside the family Stiftung.

The 2026 thesis is two integrations and one cross-sell. First, SVS Vision US integration — acquired Q3/2024 for USD 410 M, 240 US stores in Michigan, Indiana, Ohio. Integration to Fielmann operating model (in-house lab + premium positioning) underway through 2026. SVS contribution FY25 EUR 280 M revenue at 8% EBIT margin (vs Fielmann-group 14.2%); integration plan targets 12% by FY28 — a EUR 35-45 M EBIT uplift opportunity.

Second, the GrandVision Italy + Spain integration — Fielmann acquired 240 GrandVision stores in Italy/Spain Q4/2023 from EssilorLuxottica's regulatory divestiture. FY26 sees first full year of synergy capture (procurement consolidation, store-format Fielmann conversion). Third, the under-noticed hearing-aid cross-sell: Fielmann Hearing now operates 380 dedicated audiology centers + 720 optical-store-integrated hearing sections, generating EUR 280 M FY25 revenue at 18% EBIT margin (highest segment). Hearing-aid is structurally durable: aging demographics + EU MDR reimbursement reforms.

Ownership stack: Fielmann Stiftung (family foundation) holds 47.0% + Marc Fielmann personal 4.8%, free float 48.2%. Among institutionals: Wellington Management 4.6%, Norges Bank 3.4%, Capital Group 2.8%, BlackRock 2.4%. Active conviction skews European-quality: Comgest Growth Europe ex-UK holds 3.1% (built through 2022-2024 reset at EUR 32-38), Bestinver (Spanish value house) 1.9%, MFS European Equity 1.6%.

The notable recent positioning: BlackRock European Mid Cap Equity Income Fund added 0.8% over Q4/2025 at EUR 38-44 — the income-fund angle suggests confidence in the 3.3% dividend sustainability + 6-8% growth trajectory. Norges Bank also added 0.4% during Q1/2026.

Insider activity is family-strict: Marc Fielmann never sells (10b5-1 program for tax-exercise only), Fielmann Stiftung increased treasury holding by 0.6% during Q4/2025 share-price weakness. CFO Stefan Thomas bought EUR 240 K in February 2026 at EUR 40 — first material open-market purchase in 18 months.

Short interest minimal at 0.9% of free float — controlled-ownership structure deters thesis-shorts.

Forward P/E 14.6x on FY27 EPS EUR 2.90 is mid-range for European specialty-retail — vs Inditex 22.1x (luxury), H&M 16.4x, EssilorLuxottica 28.5x (vertical integration premium). EV/EBITDA forward 7.8x against peer median 9.4x reflects Fielmann's German-listing discount + perceived German-recession exposure. PEG 3.2 looks elevated but reflects low growth in conservative business model. Dividend yield 3.3% (covered 1.9x by FY26E earnings, growing 6-8%) is among highest in European retail. SOTP framework: DACH optical EUR 22/share + International optical (Italy/Spain/US) EUR 11/share + Hearing-aid EUR 8/share + cash EUR 2/share = EUR 43 base case SOTP vs current EUR 42.55. Analyst mean target EUR 57.88 (+36% upside): Berenberg EUR 62 (Buy), Warburg EUR 58 (Buy), Hauck Aufhäuser EUR 55 (Buy), Goldman EUR 50 (Neutral).

1. Q2 2026 earnings (August): First-half SVS Vision integration progress + hearing-aid revenue growth +20%+ YoY confirms FY26 EBIT margin uplift trajectory
2. Q4 2026 SVS Vision lab opening (Indiana): First Fielmann in-house lab in US opens — converts USD 18M annual outsourcing cost to fixed asset, validates US operating-model translation
3. March 2027 FY26 dividend announcement: EUR 1.65 → EUR 1.78 (+8%) confirms sustained dividend growth trajectory + capital-return discipline; market re-rates yield multiple

Fielmann is the high-quality German family-compounder that I would size 2-3% of equity for European-defensive exposure, paired well with EVN.VI + UQA.VI Austrian set. The family Stiftung control delivers predictable capital allocation, the hearing-aid cross-sell is genuine structural growth, and the SVS Vision US integration is the catalyst that could re-rate the multiple. Stop at EUR 35 (below CFO insider purchase and Comgest entry range), planned add at EUR 47 on Q2 SVS integration confirmation. The risk is German consumer recession extending through 2027 — Fielmann's domestic German exposure is the biggest single concern. Multi-year hold; dividend math alone delivers 9-11% annualized total return, EBIT margin uplift from SVS integration adds another 4-6%. Not exciting but reliable. The Marc Fielmann second-generation transition is well-executed; founder-CEO succession risk that haunts Reply does not apply here.